Completed PHASE3 INTERVENTIONAL 2-arm NCT00171314

The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer

Sponsor: Novartis Pharmaceuticals

Updated 6 times since 2017 Last updated: Mar 19, 2012 Started: Mar 31, 2004 Primary completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00171314, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Anderlecht, Belgium , Barcelona, Spain , Bonheiden, Belgium , Brasschaat, Belgium , Brussels, Belgium , Buenos Aires, Argentina , Cape Town, South Africa , Córdoba, Spain , Daegu, South Korea and 39 more locations